Neoadjuvant systemic treatment of primary angiosarcoma
Angiosarcoma is an extremely rare and aggressive malignancy. Standard of care of localized tumors includes surgery ± radiation. Despite this multimodal treatment, >50% of the angiosarcoma patients develop local or distant recurrent disease. The role of neoadjuvant systemic therapy is still controversial and we therefore performed a systematic review of the literature to define the role of neoadjuvant systemic therapy based on available evidence. We focused on the effects of neoadjuvant systemic therapy on: 1. The success of surgical resection and 2. the long-term survival. All articles published before October 2019 on Ovid Medline, Ovid Embase, Cochrane library and Scopus were evaluated. Eighteen case reports and six retrospective cohort studies were included. There were no randomized controlled trials. This literature showed a beneficial role of neoadjuvant chemotherapy on downsizing of the tumor resulting in an improvement of the resection margins, especially in patients with cardiac or cutaneous angiosarcoma. However, no definitive conclusions on survival can be drawn based on the available literature lacking any prospective randomized studies in this setting. We advise that neoadjuvant chemotherapy should be considered, since this could lead to less mutilating resections and a higher rate of free resection margins. An international angiosarcoma registry could help to develop guidelines for this rare disease.
|Keywords||Angiosarcoma, Neoadjuvant therapy, Neoadjuvant treatment, Outcome, Sarcomas|
|Persistent URL||dx.doi.org/10.3390/cancers12082251, hdl.handle.net/1765/129621|
Heinhuis, K.M. (Kimberley M.), IJzerman, N.S, van der Graaf, W.T.A, Kerst, J.M, Schrage, Y. (Yvonne), Beijnen, J.H, … van Houdt, W.J. (2020). Neoadjuvant systemic treatment of primary angiosarcoma. Cancers (Vol. 12, pp. 1–15). doi:10.3390/cancers12082251